Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Particle-based platforms for malaria vaccines.

Wu Y, Narum DL, Fleury S, Jennings G, Yadava A.

Vaccine. 2015 Dec 22;33(52):7518-24. doi: 10.1016/j.vaccine.2015.09.097. Epub 2015 Oct 11. Review.

2.

The Rising Dominance of Shigella sonnei: An Intercontinental Shift in the Etiology of Bacillary Dysentery.

Thompson CN, Duy PT, Baker S.

PLoS Negl Trop Dis. 2015 Jun 11;9(6):e0003708. doi: 10.1371/journal.pntd.0003708. eCollection 2015. Review.

3.

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

O'Ryan M, Vidal R, del Canto F, Carlos Salazar J, Montero D.

Hum Vaccin Immunother. 2015;11(3):601-19. doi: 10.1080/21645515.2015.1011578. Review.

4.

Shigella: A Highly Virulent and Elusive Pathogen.

Zaidi MB, Estrada-García T.

Curr Trop Med Rep. 2014 Jun 1;1(2):81-87.

5.

An update on vaccines against Shigella.

Ashkenazi S, Cohen D.

Ther Adv Vaccines. 2013 Sep;1(3):113-23. doi: 10.1177/2051013613500428.

6.

Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus.

Das JK, Tripathi A, Ali A, Hassan A, Dojosoeandy C, Bhutta ZA.

BMC Public Health. 2013;13 Suppl 3:S11. doi: 10.1186/1471-2458-13-S3-S11. Epub 2013 Sep 17. Review.

7.

Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Leung DT, Uddin T, Xu P, Aktar A, Johnson RA, Rahman MA, Alam MM, Bufano MK, Eckhoff G, Wu-Freeman Y, Yu Y, Sultana T, Khanam F, Saha A, Chowdhury F, Khan AI, Charles RC, Larocque RC, Harris JB, Calderwood SB, Kovác P, Qadri F, Ryan ET.

Clin Vaccine Immunol. 2013 Jun;20(6):780-8. doi: 10.1128/CVI.00035-13. Epub 2013 Mar 20.

8.

Progress and pitfalls in Shigella vaccine research.

Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL, Levine MM.

Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):245-55. doi: 10.1038/nrgastro.2013.12. Epub 2013 Feb 19. Review.

9.

A scalable method for O-antigen purification applied to various Salmonella serovars.

Micoli F, Rondini S, Gavini M, Pisoni I, Lanzilao L, Colucci AM, Giannelli C, Pippi F, Sollai L, Pinto V, Berti F, MacLennan CA, Martin LB, Saul A.

Anal Biochem. 2013 Mar 1;434(1):136-45. doi: 10.1016/j.ab.2012.10.038. Epub 2012 Nov 7.

10.

The human intestinal IgA response; burning questions.

Spencer J, Klavinskis LS, Fraser LD.

Front Immunol. 2012 May 11;3:108. doi: 10.3389/fimmu.2012.00108. eCollection 2012.

11.

Shigella flexneri infection in a newly acquired rhesus macaque (Macaca mulatta).

Lee JI, Kim SJ, Park CG.

Lab Anim Res. 2011 Dec;27(4):343-6. doi: 10.5625/lar.2011.27.4.343. Epub 2011 Dec 19.

12.

Carbohydrate vaccines: developing sweet solutions to sticky situations?

Astronomo RD, Burton DR.

Nat Rev Drug Discov. 2010 Apr;9(4):308-24. doi: 10.1038/nrd3012. Review.

13.

A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1.

Jeong KI, Zhang Q, Nunnari J, Tzipori S.

J Infect Dis. 2010 Mar 15;201(6):903-11. doi: 10.1086/650995.

14.

Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, Venkatesan MM.

Vaccine. 2010 Feb 10;28(6):1642-54. doi: 10.1016/j.vaccine.2009.11.001. Epub 2009 Nov 20.

15.

Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta).

Collins TA, Barnoy S, Baqar S, Ranallo RT, Nemelka KW, Venkatesan MM.

Comp Med. 2008 Feb;58(1):88-94.

16.

Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates.

Robbins JB, Kubler-Kielb J, Vinogradov E, Mocca C, Pozsgay V, Shiloach J, Schneerson R.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7974-8. doi: 10.1073/pnas.0900891106. Epub 2009 Apr 3.

17.

Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody.

Vulliez-Le Normand B, Saul FA, Phalipon A, Bélot F, Guerreiro C, Mulard LA, Bentley GA.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):9976-81. doi: 10.1073/pnas.0801711105. Epub 2008 Jul 10.

18.

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB.

Nat Rev Microbiol. 2007 Jul;5(7):540-53. Review.

19.

O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.

Chowers Y, Kirschner J, Keller N, Barshack I, Bar-Meir S, Ashkenazi S, Schneerson R, Robbins J, Passwell JH.

Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2396-401. Epub 2007 Feb 7. Erratum in: Proc Natl Acad Sci U S A. 2007 May 1;104(18):7729.

20.

O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a.

Kubler-Kielb J, Vinogradov E, Chu C, Schneerson R.

Carbohydr Res. 2007 Feb 26;342(3-4):643-7. Epub 2006 Nov 7.

Items per page

Supplemental Content

Write to the Help Desk